Related Experiment Video

Updated: Jun 23, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

[Clinical and laboratory aspects of the Aspirin-like defect as hereditary thrombocytopathy]

N Rolf1, P Bugert, S Gehrisch

  • 1Klinik und Poliklinik für Kinder- und Jugendmedizin, Bereich Pädiatrische Hämatologie und Onkologie, Universitätsklinikum Carl Gustav Carus, Technische Universität, 01307 Dresden.

Hamostaseologie
|May 1, 2009
PubMed

Insights

Aspirin-like defect (ALD), a platelet disorder affecting arachidonic acid metabolism, was studied in 52 individuals from 17 families. Many ALD patients experienced bleeding symptoms, highlighting the need for diagnosing platelet function defects.

Area of Science:

  • Hematology
  • Platelet Physiology
  • Molecular Medicine

Context:

  • Aspirin-like defect (ALD) is a rare hereditary platelet function disorder.
  • It stems from impaired intraplatelet arachidonic acid (AA) metabolism.
  • Understanding ALD's clinical spectrum and genetic transmission is crucial.

Purpose:

  • To characterize a larger cohort of individuals with Aspirin-like defect (ALD).
  • To analyze bleeding symptoms and platelet aggregation patterns in affected families.
  • To establish diagnostic criteria for ALD and mild ALD.

Summary:

  • This study investigated 52 individuals from 17 families, including 17 index patients with ALD.
  • Absent or reduced platelet aggregation to arachidonic acid (AA) defined ALD (≤10%) and mild ALD (11-40%).
  • Epistaxis, easy bruising, menorrhagia, and perioperative hemorrhage were common bleeding symptoms, with 75% of ALD patients experiencing at least one.

Impact:

  • Identifies ALD and mild ALD in 13 and 4 family members, respectively.
  • Highlights the significance of hereditary platelet function defects in bleeding tendencies.
  • Supports family studies for diagnosing primary hemostatic defects and differential diagnoses.
Abstract

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...